Molecule intelOpportunity: ModerateEssential

Heparin

12 brands · 12 companies · product forms

Combination product ATC: B01AB01, C05BA03, S01XA14

Opportunity snapshot

Launch attractiveness
49
Market saturation
30
Price room
100
Regulatory risk
0
12
brands
12
companies
Rs 1,556.51
median price
6
price points
15.4x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 8%

Price room

Across observed sources and strengths
CheapestRs 970
MedianRs 1,556.51
Most expensiveRs 14,942.47
Spread15.4×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 15.40x across 6 trusted points (Rs 970.0-14942.47). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 7 live products for Heparin — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(70) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

12 canonical companies and 12 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 15.40x across 6 trusted points (Rs 970.0-14942.47). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.